<DOC>
	<DOCNO>NCT03087032</DOCNO>
	<brief_summary>The present 24-week , prospective , open-label , randomize , multicenter , parallel group trial carry investigate evaluate effectiveness safety add Liraglutide v insulin Glargine prandial insulin type 2 diabetes patient treat premixed Insulin .</brief_summary>
	<brief_title>Effects Adding Liraglutide v Insulin Glargine Prandial Insulin Type 2 Diabetes Patients</brief_title>
	<detailed_description>An increase number patient type 2 diabetes treat insulin . Patients diabetes receive intensive insulin therapy various combination basal prandial insulin catch vicious common cycle , whereby insulin requirement increase time , turn contributes weight gain hypoglycemia increase insulin dose . At stage , clinician observe practical limit efficacy insulin titration alone glucose-lowering often add continue metformin reduce insulin resistance . Injectable glucagon-like peptide-1 receptor agonist ( GLP-1 RAs ) , liraglutide , relatively new addition treatment armamentarium . These drug improve glucose control insulin sensitivity contribute weight loss . Treatment basal insulin plus GLP-1RAs well-established diabetes guideline may effective add prandial insulin therapy . When GLP-1 RAs start , preemptive reduction insulin dosage 25 % 30 % patient HbA1c &lt; 9 % may reduce risk hypoglycemia . In patient uncontrolled type 2 diabetes treat high dos premix insulin , Is basal-prandial insulin therapy option treatment algorithm ? Such intensification strategy carry risk increase hypoglycaemia weight gain , associate bad long-term outcome . What effect add liraglutide HbA1c level ? There randomize , control trial use GLP-1 RAs conjunction prandial insulin , use incorporated new American Diabetes Association recommendation . To investigate evaluate effectiveness safety add Liraglutide v insulin Glargine prandial insulin type 2 diabetes patient treat premixed Insulin . The present 24-week , prospective , open-label , randomize , multicenter , parallel group trial preform .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>20≤ age≤70 year type 2 diabetes ≥6 month HbA1c &gt; =7.0 % 28≤BMI≤45kg/m2 All patient receive stable premix insulin therapy addition diet exercise without oral antihyperglycemic agent ≥12 week screen . The insulin dose require stable ( daily fluctuation 20 % ) ≥12 week screen current dose ≥30 ( I ) U/day . history pancreatic disease , lipase level &gt; 3 time normal , creatinine clearance ≤ 30 mL/min/1.73m2 , incretin therapy previous 90 day , evidence last 6 month significant heart disease stroke , include myocardial infarction , unstable angina , coronary bypass and/or percutaneous transluminal coronary angioplasty , congestive heart failure ( New York Heart Association Functional Classification IIIIV ) , severe ischemic heart disease .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Liraglutide</keyword>
	<keyword>Insulin Glargine</keyword>
	<keyword>Prandial Insulin</keyword>
</DOC>